These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 10435754)
1. Increased potency of an aptameric G-rich oligonucleotide is associated with novel functional properties of phosphorothioate linkages. Tam RC; Wu-Pong S; Pai B; Lim C; Chan A; Thomas DF; Milovanovic T; Bard J; Middleton PJ Antisense Nucleic Acid Drug Dev; 1999 Jun; 9(3):289-300. PubMed ID: 10435754 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD28 expression by oligonucleotide decoys to the regulatory element in exon 1 of the CD28 gene. Tam RC; Lin CJ; Lim C; Pai B; Stoisavljevic V J Immunol; 1999 Oct; 163(8):4292-9. PubMed ID: 10510368 [TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide-mediated inhibition of CD28 expression induces human T cell hyporesponsiveness and manifests impaired contact hypersensitivity in mice. Tam RC; Phan UT; Milovanovic T; Pai B; Lim C; Bard J; He L J Immunol; 1997 Jan; 158(1):200-8. PubMed ID: 8977191 [TBL] [Abstract][Full Text] [Related]
4. Anti-gene effect in live cells of AG motif triplex-forming oligonucleotides containing an increasing number of phosphorothioate linkages. Cogoi S; Rapozzi V; Quadrifoglio F; Xodo L Biochemistry; 2001 Feb; 40(5):1135-43. PubMed ID: 11170438 [TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Uhlmann E; Ryte A; Peyman A Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):345-50. PubMed ID: 9303186 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. Teasdale RM; Matson SJ; Fisher E; Krieg AM Antisense Res Dev; 1994; 4(4):295-7. PubMed ID: 7734945 [TBL] [Abstract][Full Text] [Related]
7. Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity. Akhtar S; Dunnion D; Poyner D; Ackroyd J; Bibby M; Double J Biochem Pharmacol; 2002 Jun; 63(12):2187-95. PubMed ID: 12110378 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells. Tamura Y; Tao M; Miyano-Kurosaki N; Takai K; Takaku H Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):87-96. PubMed ID: 10805159 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. Wu D; Boado RJ; Pardridge WM J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. Zhu FG; Reich CF; Pisetsky DS J Leukoc Biol; 2002 Apr; 71(4):686-94. PubMed ID: 11927656 [TBL] [Abstract][Full Text] [Related]
12. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922 [TBL] [Abstract][Full Text] [Related]
13. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides. Dheur S; Dias N; van Aerschot A; Herdewijn P; Bettinger T; Rémy JS; Hélène C; Saison-Behmoaras ET Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):515-25. PubMed ID: 10645777 [TBL] [Abstract][Full Text] [Related]
14. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides. Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761 [TBL] [Abstract][Full Text] [Related]
15. Guanine modification of inhibitory oligonucleotides potentiates their suppressive function. Römmler F; Jurk M; Uhlmann E; Hammel M; Waldhuber A; Pfeiffer L; Wagner H; Vollmer J; Miethke T J Immunol; 2013 Sep; 191(6):3240-53. PubMed ID: 23966630 [TBL] [Abstract][Full Text] [Related]
17. Control of DNA conformation using 3'-S-phosphorothiolate-modified linkages. Buckingham J; Sabbagh G; Brazier J; Fisher J; Cosstick R Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):491-5. PubMed ID: 16247977 [TBL] [Abstract][Full Text] [Related]
18. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Srinivasan SK; Tewary HK; Iversen PL Antisense Res Dev; 1995; 5(2):131-9. PubMed ID: 7580117 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides. Park WS; Miyano-Kurosaki N; Abe T; Takai K; Yamamoto N; Takaku H Biochem Biophys Res Commun; 2000 Apr; 270(3):953-60. PubMed ID: 10772932 [TBL] [Abstract][Full Text] [Related]
20. Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding. Cogoi S; Ballico M; Bonora GM; Xodo LE Cancer Gene Ther; 2004 Jul; 11(7):465-76. PubMed ID: 15118760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]